Objectives Despite surgical resection, chemoradiation, and targeted therapy, brain tumors
remain a leading cause of cancer-related death in children. Immunotherapy has shown …

The emergence of programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1)
immunosuppressants provides new therapeutic directions for various advanced malignant …

The advent of chimeric antigen receptor (CAR)-T cells has recently changed the prognosis
of relapsing/refractory diffuse large B-cell lymphomas, showing response rates as high as 60 …

Recent advances in research on extracellular vesicles have significantly enhanced their
potential as therapeutic agents for neurological diseases. Owing to their therapeutic …

Among the pediatric brain tumors, diffuse midline gliomas (DMG) harboring a mutation in
histone H3K27 have the deadliest prognosis [1]. These tumors are most commonly found in …

Diffuse midline glioma, H3 K27-altered (DMG-Alt) are highly aggressive malignancies of the
central nervous system (CNS) that primarily affect the pediatric population. Large scale …

Purpose Over the past several decades, numerous articles have been published on
brainstem tumors. However, there has been limited bibliometric analysis in this field …

Introduction: Clinical adoption of NK cell immunotherapy is underway for medulloblastoma
and osteosarcoma, however there is currently little feedback on cell fate after administration …

Introduction Diffuse intrinsic pontine glioma (DIPG) is the most common malignant brainstem
tumour in children. Despite advances in understanding its biology, current treatments have …

PFA ependymomas are highly aggressive brain tumors typically arising in young children
(median age 3 years) and characterized by a poor outcome (10-year OS< 60%). Standard of …